Vor Biopharma Inc. · NASDAQ:VOR
Vor Biopharma — 44th Annual J.P. Morgan Healthcare Conference 2026
19 slides from Vor Biopharma's conference presentation, Jan 12, 2026
Slide 1: Global Science. One Purpose. 44th Annual J.P. Morgan Healthcare Conference
Global Science. One Purpose. 44th Annual J.P. Morgan Healthcare Conference January 2026
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believe,” “can,” “could,” “des
Slide 3: Immune Remodulation Through BAFF/APRIL Inhibition
Immune Remodulation Through BAFF/APRIL Inhibition *Pro forma cash, cash equivalents, and short-term investments as of December 2025 OUR AMBITION To Transform the Approach to B cell-Driven Autoimmune Disease TELITACICEPT Selective BAFF/APRIL inhibitor designed to reduce pathogenic B cells and antibod
Slide 4: Dual BAFF/APRIL Inhibition Targets Autoreactive B Cells and Plasma Cells
Dual BAFF/APRIL Inhibition Targets Autoreactive B Cells and Plasma Cells BAFF, B-cell activating factor; BLyS, B Lymphocyte Stimulator; APRIL, a proliferation inducing ligand Disease modification through upstream control of B cell survival and downstream antibody production Regulated by APRIL Regula
Slide 5: Established Efficacy in China Across Autoimmune Diseases
Commercial Approvals †Conditional Approval, Full Approval in 2023; *Accelerated Approval in China Established Efficacy in China Across Autoimmune Diseases BLA Submissions Best-In-Disease 3 2 3 2021 - Systemic Lupus Erythematosus (SLE)† 2024 - Rheumatoid Arthritis (RA) 2025 - Myasthenia Gravis (MG) F
Slide 6: Favorable Safety At Scale
*From pooled safety analysis across all telitacicept trials. AEs, adverse events; SAEs, serious adverse events. Favorable Safety At Scale Favorable and Predictable Safety Profile Observed Among ~1,800* Patients Studied in Clinical Trials No Burdensome Vaccination Requirements No Signature B Cell Dep
Slide 7: Advancing the Leading BAFF/APRIL Inhibitor
RemeGen Indications Preclinical Phase 1 Phase 2 Phase 3 Marketing Approval Milestones Myasthenia Gravis (MG) OLE 48-wk Data – AANEM (10.29.25) Sjögren’s Disease (SD) LBA Poster Presentation – ACR (10.28.25) IgA Nephropathy (IgAN) LBA Oral Presentation – ASN (11.8.25) Systemic Lupus Erythematosus (SL
Slide 8: Myasthenia Gravis: Moving Beyond IgG Therapies
Myasthenia Gravis Moving Beyond IgG Therapies
Slide 9: Myasthenia Gravis: The Beachhead Indication
Myasthenia Gravis: The Beachhead Indication Telitacicept demonstrated depth, durability, and a differentiated upstream mechanism Across leading mechanisms, telitacicept demonstrates largest placebo-adjusted MG-ADL improvement 24- and 48-week data show continued improvement, suggesting patient benefi
Slide 10: Telitacicept Demonstrated Durable MG-ADL Over Time
-7.5 -6.3 -7.5 -1.6 -6.4 Mean change from baseline (95% CI) MEAN CHANGE IN MG-ADL SCORE OLE Period Patients in placebo group switched to telitacicept* Telitacicept Demonstrated Durable MG-ADL Over Time Sustained and deepening functional improvement through 48 weeks RemeGen-sponsored trial -7.5 * Tel
Slide 11: Ongoing Global Phase 3 in Generalized Myasthenia Gravis
Ongoing Global Phase 3 in Generalized Myasthenia Gravis MG-ADL, Myasthenia Gravis-Activities of Daily Living; QMG, Quantitative Myasthenia Gravis; QW, per week. *Estimated. †For patients who discontinue treatment before the open-label extension (OLE) period, end of treatment (EOT) and end of study (
Slide 12: Sjögren's Disease: Moving Beyond Symptom Management
Sjögren's Disease Moving Beyond Symptom Management
Slide 13: Sjögren's Disease: Significant Unmet Need, Limited Treatments
Sjögren’s Disease: Significant Unmet Need, Limited Treatments DMARDs, disease-modifying anti-rheumatic drugs; ESSDAI, EULAR Sjögren’s syndrome disease activity index Targeting ~100,0001 addressable patient US opportunity with a potential best-in-disease profile Interstitial pneumonia Secondary Rayna
Slide 14: A True Signal, No Noise
A True Signal, No Noise No DMARDs, no steroids Clinically Meaningful, Statistically Clear Robust, dose-dependent improvements across physician- and patient-assessed outcomes Depth and Durability Across Domains Improvement of systemic activity, symptoms, and function Consistent Safety Profile No new
Slide 15: Telitacicept Demonstrated Durable ESSDAI Over Time
-3.2 -4.6 Change from baseline (point) in essdai score over weeks 0-48⁑ -0.4 # # Ϯ # ǂ # # # # # # # # # # # # # # # # # # Telitacicept Demonstrated Durable ESSDAI Over Time Placebo*: Participants randomized to the placebo group. ⁜The analysis of change from baseline in ESSDAI score over Weeks 0-24
Slide 16: Telitacicept Demonstrated the Strongest ESSDAI Improvement in SD
Telitacicept Demonstrated the Strongest ESSDAI Improvement in SD Largest placebo-adjusted ESSDAI reduction observed across Phase II and III datasets -4.3 PBO-adjusted LSM ESSDAI Change from Baseline Efgartigimod - RHO; Nipocalimab - Bowman 2022, Lancet; Ianalumab - St. Clair 2024, Nature and Grader-
Slide 17: Significant Near-Term Expansion Opportunities
90k US diagnosed patients with Myasthenia Gravis 1. Vor metanalysis and estimates Beachhead 380k US diagnosed patients with Myasthenia Gravis and Sjögren's Disease Follow-On >1M+ US diagnosed patients with Myasthenia Gravis, Sjögren's Disease, and other B-cell mediated autoimmune disease Expansion S
Slide 18: 2026: Advancing The Leading BAFF/APRIL Inhibitor
2026: Advancing The Leading BAFF/APRIL Inhibitor *Pro forma cash, cash equivalents, and short-term investments as of December 2025 ~$450M Runway into Mid-2028* MYASTHENIA GRAVIS 01 02 SJÖGREN’S DISEASE Global Phase 3 Topline Data in 1H27 Best-in-Disease, Commercially Approved in China Global Phase 3
Slide 19: Thank You
Thank You. Investors@vorbio.com
Vor Biopharma — 44th Annual J.P. Morgan Healthcare Conference 2026 on 6ix